Tango Therapeutics, Inc. (TNGX)
22.52
-0.24
(-1.05%)
USD |
NASDAQ |
Sep 04, 16:00
22.52
0.00 (0.00%)
Pre-Market: 20:00
Tango Therapeutics Research and Development Expense (Quarterly) : 36.77M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 36.77M |
| March 31, 2026 | 33.07M |
| December 31, 2025 | 31.62M |
| September 30, 2025 | 30.26M |
| June 30, 2025 | 32.18M |
| March 31, 2025 | 36.44M |
| December 31, 2024 | 33.94M |
| September 30, 2024 | 33.26M |
| June 30, 2024 | 38.65M |
| March 31, 2024 | 38.06M |
| December 31, 2023 | 31.34M |
| September 30, 2023 | 27.15M |
| Date | Value |
|---|---|
| June 30, 2023 | 28.67M |
| March 31, 2023 | 28.04M |
| December 31, 2022 | 29.09M |
| September 30, 2022 | 28.74M |
| June 30, 2022 | 23.74M |
| March 31, 2022 | 24.33M |
| December 31, 2021 | 21.63M |
| September 30, 2021 | 21.92M |
| June 30, 2021 | 19.08M |
| March 31, 2021 | 15.00M |
| December 31, 2020 | 15.06M |
| September 30, 2020 | 12.98M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Revolution Medicines, Inc. | 392.47M |
| Erasca, Inc. | 35.90M |
| Beam Therapeutics, Inc. | 95.10M |
| NovelStem International Corp. | -- |
| Brainstorm Cell Therapeutics, Inc. | 0.917M |